Sustained release composition of therapeutic agent

• US 8,945,622 B2
• Filed: 03/05/2010
• Issued: 02/03/2015
• Est. Priority Date: 03/09/2009
• Status: Expired due to Fees

• Current Assignee: Council of Scientific & Industrial Research
• Original Assignee: Council of Scientific & Industrial Research
• Inventors: Muthusamy, Ramesh, Kulkarni, Mohan Gopalkrishna
• Primary Examiner(s): GULLEDGE, BRIAN M
• Application Number:
  US13/254,712
• Publication Number:
  US 20120107400A1
• Time in Patent Office: 1,796 Days
• Field of Search: None
• US Class Current: 424/482
• CPC Class Codes: A61K 31/167 having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 31/522 having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• CPC Class Codes: A61K 31/545 Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. cephalosporins, cefaclor, or cephalexine
• CPC Class Codes: A61K 31/554 having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 9/2853 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

A pH dependent drug delivery system comprising a pH sensitive graft copolymer, a therapeutically active agent and other pharmaceutically acceptable ingredients. More specifically, a composition which is capable of suppressing the drug release in the acidic pH prevalent in the stomach and releasing the drug over an extended period of time at pH prevalent in the intestinal region.

Claims

1. A sustained release composition for oral administration comprising:

a. a graft copolymer which exhibits pH dependent behavior having the formula 1

2. The sustained release composition as claimed in claim 1, wherein the backbone is poly (ester-ether) or polyester.

3. The sustained release composition as claimed in claim 1, wherein the diol is selected from the group consisting of aliphatic diol, cycloaliphatic diol and aromatic diol.

4. The sustained release composition as claimed in claim 3, wherein the aliphatic diol is selected from the group consisting of diethylene glycol, triethylene glycol, tetraethylene glycol, dipropylene glycol, tripropylene glycol, polyethylene glycol (M_n˜

200), polyethylene glycol (M_n˜

400), polyethylene glycol (M_n˜

1000), polyethylene glycol (M_n˜

2000), 1,2-ethane diol, 1,3-propane diol, 1,2-propane diol, 2-methyl-1,3-propane diol, 1,4-butane diol, 1,3-butane diol, 1,2-butane diol, 1,5-pentane diol, 1,6-hexane diol, 1,7-heptane diol, 1,8-octane diol, 1,9-nonane diol and 1,12-dodecane diol.

5. The sustained release composition as claimed in claim 3, wherein the cycloaliphatic diol is 1,4-cyclohexanedimethanol.

6. The sustained release composition as claimed in claim 3, wherein the aromatic diol is bis(2-hydroxyethyl) terephthalate.

7. The sustained release composition as claimed in claim 1, wherein the dicarboxylic acid is selected from the group consisting of succinic acid, glutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid and dodecanedioic acid.

8. The sustained release composition as claimed in claim 1, wherein the acid anhydride is selected from succinic anhydride and phthalic anhydride.

9. The sustained release composition as claimed in claim 1, wherein the monomer containing pendent unsaturation is an epoxy monomer or a diol monomer.

10. The sustained release composition as claimed in claim 9, wherein the epoxy monomer is selected from glycidyl methacrylate and glycidyl acrylate.

11. The sustained release composition as claimed in claim 9, wherein the diol monomer is selected from trimethylolpropane monomethacrylate and trimethylolpropane monoacrylate.

12. The sustained release composition as claimed in claim 1, wherein the acidic monomer is a carboxylic acid selected from acrylic acid and methacrylic acid.

13. The sustained release composition as claimed in claim 1, wherein the orally ingestible therapeutically active agent is selected from the group consisting of anti-inflammatory drugs, cardiovascular drugs, antibiotic drugs, analgesic drugs and anti-asthmatic drugs.

14. The sustained release composition as claimed in claim 13, wherein the anti-inflammatory drug is selected from the group consisting of ibuprofen, ketoprofen, indomethacin, diclofenac and naproxen.

15. The sustained release composition as claimed in claim 13, wherein the cardiovascular drug is selected from the group consisting of verapamil, nifedepine, captopril, propranolol, atenolol and diltiazem.

16. The sustained release composition as claimed in claim 13, wherein the antibiotic drug is selected from ampicillin and cephalexin.

17. The sustained release composition as claimed in claim 13, wherein the analgesic drug is selected from the group consisting of acetylsalicylic acid, acetaminophen, oxycodone and morphine.

18. The sustained release composition as claimed in claim 13, wherein the anti-asthmatic drug is selected from the group consisting of aminophylline, theophylline and salbutamol.

19. The sustained release composition as claimed in claim 1, wherein the orally ingestible pharmaceutically acceptable ingredient is selected from the group consisting of filler, binder, lubricant and glidant.

20. The sustained release composition as claimed in claim 19, wherein filler is selected from microcrystalline cellulose and lactose monohydrate, binder is selected from hydroxypropyl methyl cellulose and polyvinylpyrrolidone, lubricant is selected from magnesium stearate and talc and glidant is aerosil.

21. The sustained release composition as claimed in claim 1, wherein the pH sensitive graft copolymer comprises 20-50% of the total weight of the formulation.

22. The sustained release composition as claimed in claim 1, wherein the orally ingestible therapeutically active agent comprises 20-40% of the total weight of the formulation.

23. The sustained release composition as claimed in claim 1, wherein the orally ingestible pharmaceutically acceptable ingredients comprise 15-40% of the total weight of the formulation.

24. The sustained release composition as claimed in claim 1, wherein the orally ingestible pharmaceutically acceptable ingredients comprise filler 10-30%, binder 5-10%, lubricant 0.5-2% and glidant 0.2-1% of the total weight of the formulation.

25. The sustained release composition as claimed in claim 1, wherein the orally ingestible sustained release composition is produced in pharmaceutical solid dosage form.

26. The sustained release composition as claimed in claim 25, wherein the dosage form comprises an optional coat of said pH sensitive graft copolymer.

27. The sustained release composition as claimed in claim 1, wherein process for the preparation of the composition comprises the steps of:

I. dry granulating and mixing the orally ingestible therapeutically active agent, pH sensitive graft copolymer and orally ingestible pharmaceutically acceptable ingredient to obtain a granular mixture;

II. compressing the granular mixture obtained in step (I) into a tablet to obtain core tablet;

III. dissolving a pH sensitive graft copolymer and di-n-butyl phthalate in a solvent mixture to obtain a 10% solution;

IV. coating the core tablet obtained in step (II) with the 10% solution of the pH sensitive graft copolymer and di-n-butyl phthalate obtained in step (III) to obtain a coated tablet; and

V. drying the coated tablet obtained in step (IV) to obtain an orally ingestible sustained release composition.